Vertex presents new data at the european cystic fibrosis conference demonstrating significant benefits of treatment with trikafta®

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that data on trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the european union and in the u.k. as kaftrio® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, were presented at this year's european cystic fibrosis society's (ecfs) 47th european cystic fibrosis conference held june 5-8, 2024, in glasgow, scotland. data from a randomized, double-blind, phase 3 study.
VRTX Ratings Summary
VRTX Quant Ranking